Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer
NCT06072612Phase 3Recruiting
- Sponsor
- BriaCell Therapeutics Corp.
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SV-BR-1-GM in breast cancer (3 arms), sponsored by BriaCell Therapeutics Corp. Primary endpoint: Overall Survival up to 60 months. Started Dec 2023; status: recruiting.
02
Drugs
SV-BR-1-GM
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06072612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072612.